Clinical Pathways Development for Early Stage Breast Cancer: A 2011 Update of Tumor Markers and Their Use in the Community
Media:
Audio/slides with interactive questions. Printable PDF also available.
Target Audience
This activity is intended for physicians, pharmacists, nurses, and case managers from health plans, hospitals, provider groups, government programs, and other organizations with an interest in pharmacoeconomics and health policy development. It may also be useful to other clinicians and researchers working with public or private payers.
Statement of Need
Recently, the National Comprehensive Cancer Network (NCCN) released new guidance on the use of breast cancer tumor markers in breast cancer management strategies. Specifically, they provided new guidance on the role of molecular diagnostics in breast cancer treatment planning. These markers can provide a more comprehensive understanding of underlying tumor biology leading to a more individualized approach in order to direct therapy. This activity aims to review recent data relevant to risk stratification of women with early breast cancer based on risk for distal recurrence and likelihood of response to adjuvant therapy in the context of recently released NCCN guidelines and other recent updates.
Educational Objectives
Upon completion of this educational activity, participants will be able to:
- Describe some of the evidence behind the NCCN and ASCO guidelines on the management of early breast cancer related to tumor markers.
- Create a clinical pathway that addresses the use of gene expression assays in early breast cancer.
- Determine the appropriateness of multi-gene assays in supporting adjuvant therapy recommendations in early breast cancer.
Agenda
- Early Breast Cancer Treatment planning (15 minutes)
- Rationale and Evidence for the Use of Genetic Biomarkers (10 minutes)
- Clinical Pathways; Advantages, Challenges and Guidance (15 minutes)
- Update of 2010-2011 clinical data and guidelines (15 minutes)
- Evaluation (5 minutes)
Faculty Information and Disclosures
Frederick P. Smith, MDAttending Medical Oncologist,
Sibley Memorial Hospital
Clinical Associate Professor,
Georgetown University School of Medicine
Washington, DC
Dr. Smith has disclosed that he serves as a consultant for Genomic Health.
The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CE/CME activity.
Instructions
To receive a statement of credit, you must:
- Review the full content of the activity and reflect upon its teachings.
- Complete the questions and evaluation within the activity.
Your statement of credit will be issued immediately upon successful completion of the test and submission of the evaluation form.
Accreditation Statements
Physician
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and Astute Continuing Education. CEC is accredited by the ACCME to provide continuing medical education for physicians.
CEC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Statements of credit will be issued online immediately following successful completion of this activity.
Pharmacy
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity has been assigned ACPE #0245-0000-11-021-H01-P and will award 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.
Nurses
Creative Educational Concepts, Inc. (CEC) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CEC provides this activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Case Managers
This activity has been approved for 1.0 clock hour through 6/13/12 by the Commission for Case Manager Certification.
Approval #790005057
Fee
This activity is complimentary.
Disclosure Declaration
It is the policy of CEC and Astute Continuing Education to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC or Quest MedEd of any product or manufacturer identified.
Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
This activity is jointly sponsored by Creative Educational Concepts, Inc. and Astute Continuing Education, LLC.
SUPPORTING ORGANIZATION:
This activity is supported by an educational grant from Genomic Health, Inc.
REQUIRED COMPUTER HARDWARE/SOFTWARE:
